tetano
Editor, Senior Moderator
Ann Med Surg (Lond)
. 2022 Mar 3;103434.
doi: 10.1016/j.amsu.2022.103434. Online ahead of print.
COVID-19 associated with pulmonary mucormycosis; a case series
Okba F Ahmed[SUP] 1 [/SUP], Saoud Al-Neaimy[SUP] 2 [/SUP], Fahmi H Kakamad[SUP] 3 4 5 [/SUP], Razhan K Ali[SUP] 6 [/SUP], Tomas M Mikael[SUP] 3 5 [/SUP], Ahmed Gh Hamasaeed[SUP] 3 7 [/SUP], Shvan H Mohammed[SUP] 5 [/SUP], Rawezh Q Salih[SUP] 3 5 [/SUP], Abdulwahid M Salh[SUP] 3 4 [/SUP], Muhammed Gh Hamasaeed[SUP] 8 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has evolved as a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). With the rise of cases worldwide, plenty of potential COVID-19 complications have emerged, including increased susceptibility to subsequent bacterial and fungal infections. This study aims to report four cases of COVID-19 associated with pulmonary mucormycosis.
Method: This is a multi-center case series study. Diagnosis of COVID-19 was confirmed by reverse transcriptase-polymerase chain reaction.
Result: A total of 4 patients infected with SARS-CoV2 were involved in this study. The majority of the cases were female, aged >42 years old. All patients developed severe symptoms. All of the patients had received steroids, half of them had co-morbidities. The most common computerized tomography (CT) scan findings were pulmonary cavitation and empyema. All of the cases were treated with a combination of surgery and antifungal treatment.
Conclusion: As the number of COVID-19 cases rises, enhanced surveillance for co-infections with unusual pathogens should be continued. Clinicians should raise awareness of these deadly infections, which can further aggravate severe COVID-19.
Keywords: COVID-19; Fungal infection; Mucormycosis; Pulmonary complication; SARS-CoV2.
. 2022 Mar 3;103434.
doi: 10.1016/j.amsu.2022.103434. Online ahead of print.
COVID-19 associated with pulmonary mucormycosis; a case series
Okba F Ahmed[SUP] 1 [/SUP], Saoud Al-Neaimy[SUP] 2 [/SUP], Fahmi H Kakamad[SUP] 3 4 5 [/SUP], Razhan K Ali[SUP] 6 [/SUP], Tomas M Mikael[SUP] 3 5 [/SUP], Ahmed Gh Hamasaeed[SUP] 3 7 [/SUP], Shvan H Mohammed[SUP] 5 [/SUP], Rawezh Q Salih[SUP] 3 5 [/SUP], Abdulwahid M Salh[SUP] 3 4 [/SUP], Muhammed Gh Hamasaeed[SUP] 8 [/SUP]
Affiliations
- PMID: 35261764
- PMCID: PMC8891121
- DOI: 10.1016/j.amsu.2022.103434
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has evolved as a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). With the rise of cases worldwide, plenty of potential COVID-19 complications have emerged, including increased susceptibility to subsequent bacterial and fungal infections. This study aims to report four cases of COVID-19 associated with pulmonary mucormycosis.
Method: This is a multi-center case series study. Diagnosis of COVID-19 was confirmed by reverse transcriptase-polymerase chain reaction.
Result: A total of 4 patients infected with SARS-CoV2 were involved in this study. The majority of the cases were female, aged >42 years old. All patients developed severe symptoms. All of the patients had received steroids, half of them had co-morbidities. The most common computerized tomography (CT) scan findings were pulmonary cavitation and empyema. All of the cases were treated with a combination of surgery and antifungal treatment.
Conclusion: As the number of COVID-19 cases rises, enhanced surveillance for co-infections with unusual pathogens should be continued. Clinicians should raise awareness of these deadly infections, which can further aggravate severe COVID-19.
Keywords: COVID-19; Fungal infection; Mucormycosis; Pulmonary complication; SARS-CoV2.